AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 11758183 — intervention group
Group type: COMPARATOR
Intervention: Ca‐D 600 mg/d only (control)
Number of subjects: 60
Study 9731027 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmeterol
Number of subjects: 13
Study 9731027 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 7670428 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral treatment (5-week duration including relaxation training, self-monitoring of stressors, and cognitive coping strategies)
Number of subjects: 0
Study 7670428 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control condition
Number of subjects: 0
Study 2507092 — intervention group
Group type: EXPERIMENTAL
Intervention: Asthma nurse visiting homes
Number of subjects: 43
Study 2507092 — intervention group
Group type: COMPARATOR
Intervention: Control group (43 control asthmatics)
Number of subjects: 43
Study 1096396 — intervention group
Group type: EXPERIMENTAL
Intervention: Propantheline bromide
Number of subjects: 99
Study 1096396 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 99
Study 31028155 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposed FDRs (with a family history of non-advanced adenomas)
Number of subjects: 828
Study 31028155 — intervention group
Group type: COMPARATOR
Intervention: Unexposed FDRs (without a family history of adenomas)
Number of subjects: 828
Study 31028155 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposed FDRs
Number of subjects: 828
Study 31028155 — intervention group
Group type: COMPARATOR
Intervention: Unexposed FDRs
Number of subjects: 828
Study 31117989 — intervention group
Group type: EXPERIMENTAL
Intervention: ACDC (Adolescent Coping with Depression Course)
Number of subjects: 228
Study 31117989 — intervention group
Group type: COMPARATOR
Intervention: UC (Usual Care)
Number of subjects: 228
Study 28474152 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibular grafting
Number of subjects: 27
Study 28474152 — intervention group
Group type: COMPARATOR
Intervention: Core decompression
Number of subjects: 27
Study 25500307 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc supplementation (10mg daily for 18 weeks)
Number of subjects: 404
Study 25500307 — intervention group
Group type: COMPARATOR
Intervention: Placebo supplementation
Number of subjects: 404
Study 25500307 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc supplementation
Number of subjects: 404
Study 24148258 — intervention group
Group type: EXPERIMENTAL
Intervention: Tigatuzumab
Number of subjects: 97
Study 24148258 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 97
Study 21640383 — intervention group
Group type: EXPERIMENTAL
Intervention: Pterygium extended removal followed by extended conjunctival transplant
Number of subjects: 119
Study 21640383 — intervention group
Group type: COMPARATOR
Intervention: Control eyes (contralateral and otherwise normal)
Number of subjects: 119
Study 19384265 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin supplementation (2 mg of folic acid, 25 mg vitamin B6, and 400 microg of vitamin B12)
Number of subjects: 52
Study 19384265 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin supplementation
Number of subjects: 52
Study 19384265 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study 15860720 — intervention group
Group type: EXPERIMENTAL
Intervention: Humidified CPAP
Number of subjects: 31
Study 15860720 — intervention group
Group type: COMPARATOR
Intervention: Sham CPAP
Number of subjects: 31
Study 12002496 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic release by the single portal Agee technique
Number of subjects: 25
Study 12002496 — intervention group
Group type: COMPARATOR
Intervention: Open release
Number of subjects: 25
Study 10211633 — intervention group
Group type: EXPERIMENTAL
Intervention: HDL2 and HDL3 levels
Number of subjects: 0
Study 10211633 — intervention group
Group type: EXPERIMENTAL
Intervention: Triglyceride levels
Number of subjects: 0
Study 10211633 — intervention group
Group type: EXPERIMENTAL
Intervention: HDL2-C/HDL3-C ratio
Number of subjects: 0
Study 7605876 — intervention group
Group type: EXPERIMENTAL
Intervention: 35 mg Aprosulate b.i.d. s.c.
Number of subjects: 0
Study 7605876 — intervention group
Group type: EXPERIMENTAL
Intervention: 70 mg Aprosulate b.i.d. s.c.
Number of subjects: 0
Study 7605876 — intervention group
Group type: EXPERIMENTAL
Intervention: 70 mg Aprosulate o.d. + placebo o.d. s.c.
Number of subjects: 0
Study 7605876 — intervention group
Group type: COMPARATOR
Intervention: 40 mg Enoxaparin o.d. + placebo o.d. s.c.
Number of subjects: 0
Study 2083173 — intervention group
Group type: EXPERIMENTAL
Intervention: 900 mg garlic powder per day (equivalent to 2,700 mg of fresh garlic)
Number of subjects: 40
Study 2083173 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 2083173 — intervention group
Group type: EXPERIMENTAL
Intervention: 900 mg garlic powder per day
Number of subjects: 40
Study 392620 — intervention group
Group type: EXPERIMENTAL
Intervention: PGE2 500 micrograms extra-amniotically
Number of subjects: 60
Study 392620 — intervention group
Group type: EXPERIMENTAL
Intervention: PGE2 3 mg vaginal vault
Number of subjects: 60
Study 392620 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 mg PGE2 vaginal pessary
Number of subjects: 60
Study 31758268 — intervention group
Group type: EXPERIMENTAL
Intervention: sNiTi (single-file NiTi reciprocal system)
Number of subjects: 34
Study 31758268 — intervention group
Group type: COMPARATOR
Intervention: SSH (stainless steel hand file)
Number of subjects: 34
Study 31758268 — intervention group
Group type: EXPERIMENTAL
Intervention: sNiTi
Number of subjects: 34
Study 31758268 — intervention group
Group type: COMPARATOR
Intervention: SSH
Number of subjects: 34
Study 31758268 — intervention group
Group type: EXPERIMENTAL
Intervention: sNiTi and SSH
Number of subjects: 34
Study 30813440 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil (total daily dose: 1728 mg marine triglycerides, of which 588 mg EPA and 412 mg DHA, combined with 200 mg antioxidant, coenzyme Q10)
Number of subjects: 50
Study 30813440 — intervention group
Group type: COMPARATOR
Intervention: Placebo (olive oil capsules)
Number of subjects: 50
Study 28912593 — intervention group
Group type: EXPERIMENTAL
Intervention: PTT mixture (200 mg, 69% tocotrienols and 31% α-tocopherol) twice daily for 14 days
Number of subjects: 32
Study 28912593 — intervention group
Group type: COMPARATOR
Intervention: Placebo capsules
Number of subjects: 32
Study 28912593 — intervention group
Group type: EXPERIMENTAL
Intervention: PTT mixture (200 mg) postprandial
Number of subjects: 32
Study 28912593 — intervention group
Group type: COMPARATOR
Intervention: Placebo capsules postprandial
Number of subjects: 32
Study 26468121 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc-fortified filtered water delivering 2.8 mg Zn (Zn+filter)
Number of subjects: 277
Study 26468121 — intervention group
Group type: COMPARATOR
Intervention: Nonfortified filtered water (Filter)
Number of subjects: 277
Study 26468121 — intervention group
Group type: COMPARATOR
Intervention: Nonfortified nonfiltered water (Pump)
Number of subjects: 277
Study 26468121 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc-fortified filtered water (Zn+filter)
Number of subjects: 277
Study 24045780 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrauterine diluted seminal plasma (20% SP in saline)
Number of subjects: 279
Study 24045780 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 279
Study 21493261 — intervention group
Group type: EXPERIMENTAL
Intervention: Wiping the nasal atomizer tip with 70% isopropanol (group A)
Number of subjects: 34
Study 21493261 — intervention group
Group type: COMPARATOR
Intervention: Using single-use plastic atomizer tip guards (group B)
Number of subjects: 34
Study 20069916 — intervention group
Group type: EXPERIMENTAL
Intervention: beta-tricalcium phosphate (Cerasorb)
Number of subjects: 21
Study 20069916 — intervention group
Group type: COMPARATOR
Intervention: bovine-bone hydroxiapatite xenograft (Bio-oss)
Number of subjects: 21
Study 17241422 — intervention group
Group type: EXPERIMENTAL
Intervention: BTX‐A at 100 U/mL
Number of subjects: 80
Study 17241422 — intervention group
Group type: EXPERIMENTAL
Intervention: BTX‐A at 33.3 U/mL
Number of subjects: 80
Study 17241422 — intervention group
Group type: EXPERIMENTAL
Intervention: BTX‐A at 20 U/mL
Number of subjects: 80
Study 17241422 — intervention group
Group type: EXPERIMENTAL
Intervention: BTX‐A at 10 U/mL
Number of subjects: 80
Study 15491984 — intervention group
Group type: EXPERIMENTAL
Intervention: STARBRIGHT Hospital Pals group (interactive intervention group)
Number of subjects: 79
Study 15491984 — intervention group
Group type: COMPARATOR
Intervention: Modified control group (MCG)
Number of subjects: 79
Study 11158960 — intervention group
Group type: EXPERIMENTAL
Intervention: Real acupuncture
Number of subjects: 27
Study 11158960 — intervention group
Group type: COMPARATOR
Intervention: Sham acupuncture
Number of subjects: 27
Study 11158960 — intervention group
Group type: COMPARATOR
Intervention: Real acupuncture and Sham acupuncture
Number of subjects: 27
Study 9784087 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypericum perforatum (St John's wort) 0.9 mg
Number of subjects: 2
Study 9784087 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypericum perforatum (St John's wort) 1.8 mg
Number of subjects: 2
Study 9784087 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2
Study 7929810 — intervention group
Group type: EXPERIMENTAL
Intervention: Endothelin-1
Number of subjects: 12
Study 7929810 — intervention group
Group type: EXPERIMENTAL
Intervention: Norepinephrine
Number of subjects: 12
Study 2894883 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine (maximum dose 40 mg twice a day)
Number of subjects: 410
Study 2894883 — intervention group
Group type: COMPARATOR
Intervention: Atenolol (maximum dose 100 mg once a day)
Number of subjects: 410
Study 2894883 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed combination of atenolol 50 mg and nifedipine 20 mg once daily for eight weeks
Number of subjects: 410
Study 2894883 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 410
Study 2894883 — intervention group
Group type: COMPARATOR
Intervention: Atenolol
Number of subjects: 410
Study 2894883 — intervention group
Group type: EXPERIMENTAL
Intervention: Both drugs
Number of subjects: 410
Study 29974143 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous nitroglycerin infusion at increasing doses up to 40 μg/min
Number of subjects: 40
Study 29974143 — intervention group
Group type: COMPARATOR
Intervention: Intravenous nitroglycerin infusion alone
Number of subjects: 40
Study 29974143 — intervention group
Group type: EXPERIMENTAL
Intervention: Sacubitril/valsartan 200 mg bid
Number of subjects: 40
Study 26946991 — intervention group
Group type: EXPERIMENTAL
Intervention: Couples Health CoOp (CHC)
Number of subjects: 290
Study 26946991 — intervention group
Group type: COMPARATOR
Intervention: Comparison arm
Number of subjects: 290
Study 26946991 — intervention group
Group type: COMPARATOR
Intervention: WHC/MHC arm
Number of subjects: 290
Study 25582850 — intervention group
Group type: EXPERIMENTAL
Intervention: NaFeEDTA-fortified soy sauce (6 mg Fe)
Number of subjects: 60
Study 25582850 — intervention group
Group type: EXPERIMENTAL
Intervention: FeSO₄-fortified soy sauce (6 mg Fe)
Number of subjects: 60
Study 25582850 — intervention group
Group type: COMPARATOR
Intervention: No iron-fortified soy sauce (control group)
Number of subjects: 60
Study 23021797 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone add-on
Number of subjects: 98
Study 23021797 — intervention group
Group type: COMPARATOR
Intervention: Sulfonylureas add-on
Number of subjects: 98
Study 20677441 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo effect
Number of subjects: 0
Study 20677441 — intervention group
Group type: COMPARATOR
Intervention: Drug effect
Number of subjects: 0
Study 18800883 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled sodium pyruvate
Number of subjects: 0
Study 18800883 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 15985101 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed sumatriptan injection (6 mg) followed by ketorolac infusion (two 15-mg boluses) 4 hours after onset of attack.
Number of subjects: 28
Study 15985101 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed ketorolac monotherapy (two 15-mg boluses) 4 hours after onset of attack.
Number of subjects: 28
Study 15985101 — intervention group
Group type: EXPERIMENTAL
Intervention: Infusion of COX1/COX2 inhibitors (ketorolac 0.4 mg/kg or indomethacin 1 mg/kg) in rats.
Number of subjects: 28
Study 12455318 — intervention group
Group type: EXPERIMENTAL
Intervention: Metamizol (2 g intravenous)
Number of subjects: 60
Study 12455318 — intervention group
Group type: COMPARATOR
Intervention: Propacetamol (2 g intravenous)
Number of subjects: 60
Study 10528949 — intervention group
Group type: EXPERIMENTAL
Intervention: One-to-One midwifery practice
Number of subjects: 1403
Study 10528949 — intervention group
Group type: COMPARATOR
Intervention: Conventional maternity care
Number of subjects: 1403
Study 7670399 — intervention group
Group type: EXPERIMENTAL
Intervention: Detection of malignant B cells in PBSC samples after chemotherapy
Number of subjects: 22
Study 7670399 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta 2 microglobulin serum level correlation
Number of subjects: 22
Study 7670399 — intervention group
Group type: EXPERIMENTAL
Intervention: Grafting of patients
Number of subjects: 22
Study 7670399 — intervention group
Group type: EXPERIMENTAL
Intervention: Prognosis of patients with PBSC contamination
Number of subjects: 22
Study 2289218 — intervention group
Group type: EXPERIMENTAL
Intervention: 1,200 mg of citicoline daily plus usual dose of levodopa (mean, 381 mg daily)
Number of subjects: 85
Study 2289218 — intervention group
Group type: COMPARATOR
Intervention: Half their usual dose of levodopa (mean, 196 mg daily) plus citicoline
Number of subjects: 85
Study 7395839 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam 5 mg
Number of subjects: 25
Study 7395839 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam 10 mg
Number of subjects: 25
Study 7395839 — intervention group
Group type: COMPARATOR
Intervention: Intravenous saline
Number of subjects: 25
Study 31385920 — intervention group
Group type: EXPERIMENTAL
Intervention: Recommendations by expert faculty
Number of subjects: 197
Study 31385920 — intervention group
Group type: EXPERIMENTAL
Intervention: Recommendations for treatment
Number of subjects: 197
Study 31385920 — intervention group
Group type: EXPERIMENTAL
Intervention: Knowledge translation process
Number of subjects: 197
Study 28789490 — intervention group
Group type: EXPERIMENTAL
Intervention: Testa triticum tricum purif (3.5 g bid)
Number of subjects: 122
Study 28789490 — intervention group
Group type: COMPARATOR
Intervention: Polyethylene glycol 4000 (PEG4000, 10g bid)
Number of subjects: 122
Study 25762057 — intervention group
Group type: EXPERIMENTAL
Intervention: probe‐based CLE (pCLE)
Number of subjects: 513
Study 25762057 — intervention group
Group type: COMPARATOR
Intervention: endoscope‐based CLE (eCLE)
Number of subjects: 513
Study 23660085 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramosetron combined with midazolam at induction of anaesthesia (group RM1)
Number of subjects: 126
Study 23660085 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramosetron combined with midazolam at the end of surgery (group RM2)
Number of subjects: 126
Study 23660085 — intervention group
Group type: COMPARATOR
Intervention: Ramosetron alone (group R)
Number of subjects: 126
Study 20831662 — intervention group
Group type: EXPERIMENTAL
Intervention: Fecal occult blood test with stop screen design
Number of subjects: 86150
Study 19712191 — intervention group
Group type: EXPERIMENTAL
Intervention: Leaflet containing child‐friendly dental information (experimental group)
Number of subjects: 50
Study 19712191 — intervention group
Group type: COMPARATOR
Intervention: Leaflet with child‐friendly information on the benefits of healthy eating (control group)
Number of subjects: 50
Study 18022061 — intervention group
Group type: EXPERIMENTAL
Intervention: 10,000 Steps Ghent intervention
Number of subjects: 660
Study 18022061 — intervention group
Group type: COMPARATOR
Intervention: Comparison community
Number of subjects: 660
Study 15163110 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonographically guided peritendinous injection of steroid
Number of subjects: 48
Study 15163110 — intervention group
Group type: COMPARATOR
Intervention: Placebo injection
Number of subjects: 48
Study 11352337 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipramine 150 mg/day
Number of subjects: 55
Study 11352337 — intervention group
Group type: COMPARATOR
Intervention: Sertraline 50 mg/day
Number of subjects: 55
Study 11024375 — intervention group
Group type: EXPERIMENTAL
Intervention: ETHI (video-assisted dissector)
Number of subjects: 66
Study 11024375 — intervention group
Group type: EXPERIMENTAL
Intervention: AUTS (light coupled retractor)
Number of subjects: 66
Study 11024375 — intervention group
Group type: COMPARATOR
Intervention: CONV (traditional open technique)
Number of subjects: 66
Study 9193370 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron plus metopimazine
Number of subjects: 111
Study 9193370 — intervention group
Group type: COMPARATOR
Intervention: Ondansetron alone
Number of subjects: 111
Study 1524965 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled frusemide
Number of subjects: 8
Study 1524965 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 8
Study 3889257 — intervention group
Group type: EXPERIMENTAL
Intervention: Benzathine penicillin intramuscularly plus rifampin orally (10 mg/kg twice a day for eight doses)
Number of subjects: 38
Study 3889257 — intervention group
Group type: COMPARATOR
Intervention: Benzathine penicillin intramuscularly
Number of subjects: 38
Study 3889257 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 38
Study 3889257 — intervention group
Group type: EXPERIMENTAL
Intervention: Benzathine penicillin intramuscularly plus rifampin
Number of subjects: 38
Study 29146743 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab + Methotrexate (MTX)
Number of subjects: 926
Study 29146743 — intervention group
Group type: COMPARATOR
Intervention: Methotrexate (MTX) monotherapy
Number of subjects: 926
Study 26776435 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrinogen 5.5mg and thrombin 2IU applied as a tissue sealant and gastrointestinal reinforcement sutures (Group B)
Number of subjects: 73
Study 26776435 — intervention group
Group type: COMPARATOR
Intervention: Control group (Group A)
Number of subjects: 73
Study 25375075 — intervention group
Group type: EXPERIMENTAL
Intervention: Coenzyme Q10 supplementation (50 mg twice daily)
Number of subjects: 50
Study 25375075 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 22498211 — intervention group
Group type: EXPERIMENTAL
Intervention: Real-time elastography guided biopsy
Number of subjects: 353
Study 22498211 — intervention group
Group type: COMPARATOR
Intervention: Gray scale ultrasound guided biopsy
Number of subjects: 353
Study 20102894 — intervention group
Group type: EXPERIMENTAL
Intervention: CRP levels > or =2 mg/L
Number of subjects: 30329
Study 20102894 — intervention group
Group type: COMPARATOR
Intervention: CRP levels <2 mg/L
Number of subjects: 30329
Study 18594354 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-octyl-cyanoacrylate skin adhesive (Dermabond)
Number of subjects: 50
Study 15982146 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-session parent-education program
Number of subjects: 0
Study 15982146 — intervention group
Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 0
Study 11858610 — intervention group
Group type: EXPERIMENTAL
Intervention: Latanoprost 0.005% eye drops once a day in both eyes for 4 months
Number of subjects: 14
Study 11858610 — intervention group
Group type: COMPARATOR
Intervention: Unpreserved substitute tears eye drops (Aquasalina) with the same posology and concentration of benzalkonium chloride (0.02%)
Number of subjects: 14
Study 10408559 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac/misoprostol (D/M)
Number of subjects: 41
Study 10408559 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study 7674143 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose SH/TA-508 (1.5-1.6g galactose)
Number of subjects: 196
Study 7674143 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose SH/TA-508 (3.0-3.2g galactose)
Number of subjects: 196
Study 7674143 — intervention group
Group type: COMPARATOR
Intervention: SH/TA-508 at 200 mg/ml concentration
Number of subjects: 196
Study 7674143 — intervention group
Group type: EXPERIMENTAL
Intervention: SH/TA-508 at 300 mg/ml concentration
Number of subjects: 196
Study 7674143 — intervention group
Group type: EXPERIMENTAL
Intervention: SH/TA-508 at 400 mg/ml concentration
Number of subjects: 196
Study 7674143 — intervention group
Group type: EXPERIMENTAL
Intervention: Color Doppler echocardiography with SH/TA-508
Number of subjects: 196
Study 7674143 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher doses and concentrations of SH/TA-508
Number of subjects: 196
Study 7674143 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimum concentration for two-dimensional echocardiography
Number of subjects: 196
Study 7674143 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimum concentration for color Doppler echocardiography
Number of subjects: 196
Study 2402834 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive social assistance for five months in cooperation with the general practitioner
Number of subjects: 100
Study 2402834 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intensive social assistance)
Number of subjects: 100
Study 30737585 — intervention group
Group type: EXPERIMENTAL
Intervention: day‐3 hatching‐based TE biopsy
Number of subjects: 221
Study 30737585 — intervention group
Group type: COMPARATOR
Intervention: new biopsy group (TE biopsy without hatching)
Number of subjects: 221
Study 27636913 — intervention group
Group type: EXPERIMENTAL
Intervention: 20% sucrose solution
Number of subjects: 33
Study 27636913 — intervention group
Group type: EXPERIMENTAL
Intervention: milk
Number of subjects: 33
Study 27636913 — intervention group
Group type: COMPARATOR
Intervention: water
Number of subjects: 33
Study 26886521 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone gel
Number of subjects: 790
Study 26886521 — intervention group
Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 790
Study 24650818 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol use (every drink consumed above one's mean)
Number of subjects: 120